中枢神経系の共同研究・ライセンシング契約（2020年～2025年）

当レポートでは、世界のバイオ医薬品業界について調査分析し、2020年～2025年の中枢神経系の共同研究・ライセンシング契約811件に関する、契約条件などの詳細なデータを提供しています。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 中枢神経系契約の動向

• イントロダクション
• 過去数年の中枢神経系パートナー契約
• 中枢神経系パートナー契約：契約タイプ別
• 中枢神経系パートナー契約：産業部門別
• 中枢神経系パートナー契約：開発段階別
• 中枢神経系パートナー契約：技術タイプ別
• 中枢神経系パートナー契約：適応症別

第3章 中枢神経系パートナー契約に関する財務的契約条件

• イントロダクション
• 中枢神経系パートナー契約に関する公開された財務条件
• 中枢神経系パートナー契約のヘッドライン金額
• 中枢神経系契約の前払い
• 中枢神経系契約のマイルストーン払い
• 中枢神経系のロイヤルティ率

第4章 主な中枢神経系契約と交渉者

• イントロダクション
• 中枢神経系パートナー契約分野においてもっとも活発
• 中枢神経系分野におけるもっとも活発な交渉者のリスト
• 上位の中枢神経系契約（金額）

第5章 中枢神経系契約文書ディレクトリ

• イントロダクション
• 契約書が入手可能な中枢神経系パートナー契約

第6章 中枢神経系契約：治療標的別

• イントロダクション
• 契約：中枢神経系治療標的別
• 契約ディレクトリ
• 契約ディレクトリ - 中枢神経系契約：企業別（A～Z）（2020年～2025年）
• 契約ディレクトリ - 中枢神経系契約：技術タイプ別（2020年～2025年）
• 契約タイプの定義
• Biopharma Research Ltdについて
• Current Partnering
• Current Agreements
• Current Partneringからの近年のレポートのタイトル

Central Nervous System Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the central nervous system deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 811 central nervous system deals from 2020 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of central nervous system dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in central nervous system dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the central nervous system field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in central nervous system dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of central nervous system deals signed and announced since 2020 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of central nervous system deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in central nervous system deal making since 2020.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Central Nervous System Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2020
• Browse central nervous system collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Central Nervous System Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of central nervous system trends and structure of deals entered into by leading biopharma companies worldwide.

Central Nervous System Collaboration and Licensing Deals includes:

• Trends in central nervous system dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of central nervous system deal records covering pharmaceutical and biotechnology
• The leading central nervous system deals by value
• Most active central nervous system licensing dealmakers

In Central Nervous System Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Central Nervous System Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in central nervous system dealmaking

• 2.1. Introduction
• 2.2. Central nervous system partnering over the years
• 2.3. Central nervous system partnering by deal type
• 2.4. Central nervous system partnering by industry sector
• 2.5. Central nervous system partnering by stage of development
• 2.6. Central nervous system partnering by technology type
• 2.7. Central nervous system partnering by therapeutic indication

Chapter 3 - Financial deal terms for central nervous system partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for central nervous system partnering
• 3.3. Central nervous system partnering headline values
• 3.4. Central nervous system deal upfront payments
• 3.5. Central nervous system deal milestone payments
• 3.6. Central nervous system royalty rates

Chapter 4 - Leading central nervous system deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in central nervous system partnering
• 4.3. List of most active dealmakers in central nervous system
• 4.4. Top central nervous system deals by value

Chapter 5 - Central nervous system contract document directory

• 5.1. Introduction
• 5.2. Central nervous system partnering deals where contract document available

Chapter 6 - Central nervous system dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by central nervous system therapeutic target
• Deal Directory
• Deal Directory - Central nervous system deals by company A-Z 2020 to 2025
• Deal Directory - Central nervous system deals by technology type 2020 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Central nervous system partnering since 2020
• Figure 2: Central nervous system partnering by deal type since 2020
• Figure 3: Central nervous system partnering by industry sector since 2020
• Figure 4: Central nervous system partnering by stage of development since 2020
• Figure 5: Central nervous system partnering by technology type since 2020
• Figure 6: Central nervous system partnering by indication since 2020
• Figure 7: Central nervous system deals with a headline value
• Figure 8: Central nervous system deals with upfront payment values
• Figure 9: Central nervous system deals with milestone payment
• Figure 10: Central nervous system deals with royalty rates
• Figure 11: Active central nervous system dealmaking activity since 2020
• Figure 12: Top central nervous system deals by value since 2020